DALLAS, Jan. 5, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hologic Inc. (Nasdaq:HOLX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.investorsoup.com/lp/HOLX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Hologic Inc. (HOLX) is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. It operates in four segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Company had developed a breast imaging platform, Dimensions, which utilizes a technology, tomosynthesis, to produce three dimensional (3D) images, as well as conventional two dimensional (2D) full field digital mammography (FFDM) images. On August 27, 2009, it received the U.S. Food & Drug Administration (FDA) clearance for its MammoSite ML radiation therapy system, a multi-lumen device. In July 2009, it received FDA approval of the Adiana System.
Message Board Search for HOLX: http://www.boardcentral.com/boards/HOLX
In the report, the analyst notes:
"Fourth quarter fiscal 2009 revenues totaled $402.8 million, a decrease of 9.0% when compared to revenues of $442.5 million in the fourth quarter of fiscal 2008. The decrease was primarily attributable to the year-over-year decline in sales of Selenia systems. The Company said it believes this decline continues to be due, in large part, to the current economic environment and the resulting delays and reductions in hospital capital spending as compared to the same period in the prior fiscal year."
"HOLX last month announced that the jury in the patent infringement lawsuit against SenoRx brought by HOLX, Cytyc Corp., and Hologic L.P. Inc. in the U.S. District Court for the Northern District of California has returned a verdict in favor of SenoRx. The suit alleges SenoRx's Contura infringes claims 4 and 8 of U.S. Patents 6,413,204 and 6,482,142, respectively. The jury found that claim 4 was not infringed and found that both claims were not valid. SenoRx had previously admitted infringement of claim 8. HOLX plans to appeal the matter to the Court of Appeals for the Federal Circuit."
To read the entire report visit: http://www.investorsoup.com/lp/HOLX
See what investors are saying about HOLX at penny stock forum.
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.